E73 476
[3]
Choueiri TK, Escudier B, Powles T, et al. Cabozantinib versus ever- olimus in advanced renal cell carcinoma (METEOR): final results from a randomized, open-label, phase 3 trial. Lancet Oncol 2016;17:917–27.
[4]
Gerlinger M, Rowan AJ, Horswell S, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012;366:883–92.[5]
Keizman D, Gottfried M, Ish-Shalom M, et al. Active smoking may negatively affect response rate, progression-free survival, and over- all survival of patients with metastatic renal cell carcinoma treated with sunitinib. Oncologist 2014;19:51–60.
[6]
Alexandrov LB, Ju YS, Haase K, et al. Mutational signatures associ- ated with tobacco smoking in human cancer. Science 2016;354: 618–22.
Ye Lei
a
Serdar Yildiz
b
Minfeng Chen
a,
*
a
Department of Urology, Xiangya Hospital, Central South University,
Changsha, P.R. China
b
Department of Urology, Diakonie Klinikum Stuttgart, Stuttgart, Germany
*Corresponding author. Department of Urology, Xiangya Hospital,
Central South University
[3_TD$DIFF]
, Changsha 410008,
Hunan, P.R. China. Tel. +86 13517319380.
E-mail address:
minfengchen1234@163.com(M. Chen).
January 3, 2017
E U R O P E A N U R O L O G Y 7 2 ( 2 0 1 7 ) e 7 2 – e 7 3
e73